ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Ovid, Angelini Pharma Announce Agreement for OV101 americanpharmaceuticalreview
July 22, 2020Ovid Therapeutics and Angelini Pharma announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries.. -
Ovid, Angelini Pharma Enter Exclusive License Agreement contractpharma
July 14, 2020To develop, manufacture and commercialize OV101 for the treatment of Angelman Syndrome in Europe.
Pharma Sources Insight January 2025
